In a report released on April 2, Michael Cherny from Leerink Partners maintained a Buy rating on McKesson (MCK – Research Report), with a price ...

Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Nurix Therapeutics (NRIX – Research Report) on April 2. The company’s ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

AirSculpt Technologies (NASDAQ:AIRS – Get Free Report) had its price target decreased by equities research analysts at Leerink Partners from $6.50 to $2.50 in a research note issued to investors on ...

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective dropped by Leerink Partners from $19.00 to $18.00 ...

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink Partners analysts said that the risks from Trump’s tariffs on the biopharma ...

and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place ...

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. A live webcast of the presentation may be accessed via the Investors ...

BAAR, Switzerland, March 04, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11 ...